Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Brianna Denton

Brianna Denton

Manager, Regulatory

Cancer Center Division

Collaboration(24)

Rachna Shroff
Hina Arif Tiwari
Michele Chu-Pilli
Clara Curiel
Edward Gelmann

Page 1 of 5

Grants(19)

A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed O
Active·2024·$0 / $2.2M·
External
prostate cancer, clinical trial, treatment comparison, metastatic cancer, hormone therapy
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
Active·2024·$0 / $625.4K·
External
oncology, clinical trial, drug combination, efficacy, patient safety
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment -na?ve or Pre-treated Advanced D
Active·2024·$0 / $503K·
External
drug efficacy, cancer treatment, clinical trial, drug safety, medical research
A Phase 1/2 Open-Label, Multicenter, Global Trial to Characterize the Safety, Tolerability and Preliminary Efficacy of CFT1946 as a Monotherapy and in Combination with Trametinib in Subjects with BRAF
Active·2024·$0 / $433.9K·
External
drug development, oncology, clinical trials, pharmacology, precision medicine
A Phase Ia.Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advance or Metastatic Solid Tumors
Active·2024·$0 / $20.2K·
External
cancer, clinical trial, oncology, drug development, precision medicine

Page 1 of 4